British Biotech: Difference between revisions
Content deleted Content added
Cyberbot II (talk | contribs) Rescuing 1 sources, flagging 0 as dead, and archiving 0 sources. #IABot |
m refs, typo(s) fixed: British based → British-based using AWB |
||
| Line 17: | Line 17: | ||
}} |
}} |
||
'''British Biotech''' was a British |
'''British Biotech''' was a British-based [[biotech]]nology company founded as ''British Biotechnology Limited'' in 1986 by former [[G. D. Searle & Company|G D Searle]] managers Keith McCullagh and Brian Richards.<ref name="searle">{{cite web|last= |first= |authorlink= |author2=Michael S. Rosen |year=2003 |url=http://www.midwestbusiness.com/printer/article.asp?newsletterID=4627 |title=The Final Death Knell of Chicago's G.D. Searle |work= |publisher=Midwest Business |accessdate=12 May 2003 |deadurl=yes |archiveurl=https://web.archive.org/20070927070247/http://www.midwestbusiness.com/printer/article.asp?newsletterID=4627 |archivedate=27 September 2007 }}</ref> |
||
It was the first British biotech company to be publicly listed when it was floated on 1 July 1992.<ref name="ipo">{{cite web |
It was the first British biotech company to be publicly listed when it was floated on 1 July 1992.<ref name="ipo">{{cite web |
||
| last = |
|||
| first = |
|||
| authorlink = |
|||
| year = 1992 |
| year = 1992 |
||
| url = http://www.nea.com/PortfolioCompanies/SummaryReports/IPO/index.cfm?SR=88 |
| url = http://www.nea.com/PortfolioCompanies/SummaryReports/IPO/index.cfm?SR=88 |
||
| Line 43: | Line 40: | ||
| accessdate = 8 March 2006 |
| accessdate = 8 March 2006 |
||
}}</ref> largely on the basis of its two main development drugs: ''[[marimastat]]'' (a novel [[Matrix metalloproteinase#Inhibitors|matrix metalloprotease inhibitor]] for cancer treatment<ref name="jco">{{cite web |
}}</ref> largely on the basis of its two main development drugs: ''[[marimastat]]'' (a novel [[Matrix metalloproteinase#Inhibitors|matrix metalloprotease inhibitor]] for cancer treatment<ref name="jco">{{cite web |
||
| ⚫ | |||
| last = |
|||
| first = |
|||
| authorlink = |
|||
| ⚫ | |||
| year = 1998 |
|||
| url = http://www.jco.org/cgi/content/abstract/16/6/2150 |
| url = http://www.jco.org/cgi/content/abstract/16/6/2150 |
||
| title = Phase I trial of Marimastat |
| title = Phase I trial of Marimastat |
||
| Line 56: | Line 49: | ||
In February 1998, Dr Andrew Millar was dismissed as Head of Clinical Research and went on to make allegations that "the Board were running a business plan consistent only with extreme and unfounded optimism".<ref name="report">{{cite web |
In February 1998, Dr Andrew Millar was dismissed as Head of Clinical Research and went on to make allegations that "the Board were running a business plan consistent only with extreme and unfounded optimism".<ref name="report">{{cite web |
||
| last = |
|||
| first = |
|||
| authorlink = |
|||
| year = 1998 |
| year = 1998 |
||
| url = http://www.publications.parliament.uk/pa/cm199798/cmselect/cmsctech/888/88804.htm |
| url = http://www.publications.parliament.uk/pa/cm199798/cmselect/cmsctech/888/88804.htm |
||
| Line 68: | Line 58: | ||
Subsequent investigations by the [[Securities and Exchange Commission]], [[Food and Drug Administration]], [[London Stock Exchange]] and the [[European Medicines Evaluation Agency]] found that British Biotech had wilfully misled the public about the progress of marimastat<ref name="sec">{{cite web |
Subsequent investigations by the [[Securities and Exchange Commission]], [[Food and Drug Administration]], [[London Stock Exchange]] and the [[European Medicines Evaluation Agency]] found that British Biotech had wilfully misled the public about the progress of marimastat<ref name="sec">{{cite web |
||
| last = |
|||
| first = |
|||
| authorlink = |
|||
| year = 1999 |
| year = 1999 |
||
| url = http://www.nature.com/nbt/journal/v17/n7/full/nbt0799_624b.html |
| url = http://www.nature.com/nbt/journal/v17/n7/full/nbt0799_624b.html |
||
| Line 89: | Line 76: | ||
| accessdate = 15 February 1999 |
| accessdate = 15 February 1999 |
||
}}</ref> Marimastat underwent [[Clinical trial#Phase III|Phase III trials]] in collaboration with [[Schering-Plough|Schering-Plough Corporation]].<ref name="marupdate">{{cite web |
}}</ref> Marimastat underwent [[Clinical trial#Phase III|Phase III trials]] in collaboration with [[Schering-Plough|Schering-Plough Corporation]].<ref name="marupdate">{{cite web |
||
| last = |
|||
| first = |
|||
| authorlink = |
|||
| year = 2001 |
| year = 2001 |
||
| url = http://www.mult-sclerosis.org/news/May2001/MMPIPhaseIIICancerTrialMMPIsMaybeUsefulinMS.html |
| url = http://www.mult-sclerosis.org/news/May2001/MMPIPhaseIIICancerTrialMMPIsMaybeUsefulinMS.html |
||
| Line 100: | Line 84: | ||
}}</ref> |
}}</ref> |
||
Further development of zacutex was abandoned due to poor clinical trial results.<ref name="zaputex">{{cite web |
Further development of zacutex was abandoned due to poor clinical trial results.<ref name="zaputex">{{cite web |
||
| last = |
|||
| first = |
|||
| authorlink = |
|||
| year = 1998 |
| year = 1998 |
||
| url = http://www.bbcactive.com/BroadCastLearning/asp/catalogue/productdetail.asp?productcode=21241 |
| url = http://www.bbcactive.com/BroadCastLearning/asp/catalogue/productdetail.asp?productcode=21241 |
||
| Line 112: | Line 93: | ||
The corporate politics behind the downfall of British Biotech was later recorded for a [[BBC2]] Series ''Blood on the Carpet''.<ref name="bloodcarpet">{{cite web |
The corporate politics behind the downfall of British Biotech was later recorded for a [[BBC2]] Series ''Blood on the Carpet''.<ref name="bloodcarpet">{{cite web |
||
| last = |
|||
| first = |
|||
| authorlink = |
|||
| year = 2001 |
| year = 2001 |
||
| url = http://www.bbcactive.com/BroadCastLearning/asp/catalogue/productdetail.asp?productcode=21241 |
| url = http://www.bbcactive.com/BroadCastLearning/asp/catalogue/productdetail.asp?productcode=21241 |
||
Revision as of 03:38, 8 June 2016
| Industry | Biotechnology |
|---|---|
| Founded | 1986 |
| Defunct | 2003 |
| Fate | Merged |
| Successor | company merged into Vernalis |
| Headquarters | Oxford, United Kingdom |
Key people | CEO Keith McCullagh, 1986–1998 Elliot Goldstein, 1998–2002 Tim Edwards, 2002–2003 Chair Brian Richards, 1986–1998 Christopher Hampson, 1998–2002 Peter Fellner, 2002–2003 |
Number of employees | 500 |
British Biotech was a British-based biotechnology company founded as British Biotechnology Limited in 1986 by former G D Searle managers Keith McCullagh and Brian Richards.[1] It was the first British biotech company to be publicly listed when it was floated on 1 July 1992.[2]
Controversy
In 1996, despite having no compounds on or near the market, the company was temporarily valued at nearly $2.5 billion,[3] largely on the basis of its two main development drugs: marimastat (a novel matrix metalloprotease inhibitor for cancer treatment[4]) and zacutex (for pancreatitis).
In February 1998, Dr Andrew Millar was dismissed as Head of Clinical Research and went on to make allegations that "the Board were running a business plan consistent only with extreme and unfounded optimism".[5] These events were the subject of an inquiry by the House of Commons Select Committee on Science and Technology in August 1998 which absolved Dr Millar of any responsibility for the company's problems.[5]
Subsequent investigations by the Securities and Exchange Commission, Food and Drug Administration, London Stock Exchange and the European Medicines Evaluation Agency found that British Biotech had wilfully misled the public about the progress of marimastat[6] and that unblinding data before the end of clinical trials does not necessarily invalidate the results.[7] Marimastat underwent Phase III trials in collaboration with Schering-Plough Corporation.[8] Further development of zacutex was abandoned due to poor clinical trial results.[9]
The corporate politics behind the downfall of British Biotech was later recorded for a BBC2 Series Blood on the Carpet.[10]
Disappearance
In 2003, British Biotech merged with RiboTargets and then into Vernalis. The British Biotech company name disappeared after this merger and remaining staff integrated into the Vernalis organisation in Winnersh, Berkshire.
External links
References
- ^ Michael S. Rosen (2003). "The Final Death Knell of Chicago's G.D. Searle". Midwest Business. Archived from the original on 27 September 2007. Retrieved 12 May 2003.
{{cite web}}: Missing|author1=(help); Unknown parameter|deadurl=ignored (|url-status=suggested) (help) - ^ "BBIOY IPO". IPO Summary Report. NEA. 1992. Retrieved 1 December 1992.
{{cite web}}: Check date values in:|accessdate=(help) - ^ John Hodgson (2006). "Ten years of biotech gaffes". Nature Biotechnology. Nature Publishing Group. Retrieved 8 March 2006.
{{cite web}}: Missing|author1=(help) - ^ Wojtowicz-Praga S; Torri J; Johnson M; Steen V; Marshall J; Ness E; Dickson R; Sale M; Rasmussen HS; Chiodo TA; Hawkins MJ. (1998). "Phase I trial of Marimastat". Journal of Clinical Oncology. American Society of Clinical Oncology. Retrieved 16 June 1998.
{{cite web}}: Check date values in:|accessdate=(help) - ^ a b "Fifth Report". Select Committee on Science and Technology. House of Commons. 1998. Retrieved 13 August 1998.
{{cite web}}: Check date values in:|accessdate=(help) - ^ "British Biotech settles up". Nature Biotechnology. Nature Publishing Group. 1999. Retrieved 18 July 1999.
{{cite web}}: Check date values in:|accessdate=(help) - ^ Alex Khan (1999). "Shedding Biotech's Bad Name". IP/IT Update. NIPC. Retrieved 15 February 1999.
{{cite web}}: Check date values in:|accessdate=(help); Missing|author1=(help) - ^ "Marimastat Update". BusinessWire. 2001. Retrieved 2 May 2001.
- ^ "Zacutex UK Phase III clinical data presented at American Gastroenterological Association". Select Committee on Science and Technology. House of Commons. 1998. Retrieved 14 September 1998.
{{cite web}}: Check date values in:|accessdate=(help) - ^ "BBC2's Blood on the Carpet". BBC. 2001. Retrieved 2001.
{{cite web}}: Check date values in:|accessdate=(help)